LoadingLoadingLoadingNet selling: insiders sold $240K and bought $0 on the open market in 90 days (SEC Form 4). Congress: both buying and selling, $69K to $210K in total in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full results8 funds hold a position and insiders have been net selling.
Buys/Adds (1)
Citadel
$65.1M
added
Sells/Trims (2)
Point72
$129.4M
trimmed
Balyasny
$61.9M
trimmed
Sells (1)
Minor Lloyd
$240K
sold
Top-trader positions in BIIB could not be loaded.
Hyperliquid positioning - not every stock is covered
Last report
Jul 29, 2026
Financial period
Q2 2026
Earnings per share
$2.03 expected
Revenue
Financial statements: Alpha Vantage
Estimates as of Oct 24, 2026
EPS expected
$1.44 to $2.67
Revenue expected
27 analysts
Last 30 days
Split both ways
Estimate drift
Change in 30 days
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / income | Surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Jul 29, 2026 | $3.60 / $2.03Yahoo Finance | +77.38% beat | $2.74B No estimate | Unavailable |
| Mar 31, 2026 | Apr 29, 2026 | $3.57 / $2.95Yahoo Finance | +20.93% beat | $2.48B No estimate | Unavailable |
| Dec 31, 2025 | Feb 6, 2026 | $1.99 / $1.62Yahoo Finance | +23.18% beat | $2.28B No estimate | Unavailable |
| Sep 30, 2025 | Oct 30, 2025 | $4.81 / $3.88Yahoo Finance | +23.88% beat | $2.45B No estimate | Unavailable |
| Jun 30, 2025 | Jul 31, 2025 | $5.47 / $3.88Alpha Vantage | +40.98% beat | $2.65B No estimate | Unavailable |
| Mar 31, 2025 | May 1, 2025 | $3.02 / $2.95Alpha Vantage | +2.37% beat | $2.43B No estimate | Unavailable |
| Dec 31, 2024 | Feb 12, 2025 | $3.44 / $3.36Alpha Vantage | +2.38% beat | $2.45B No estimate | Unavailable |
| Sep 30, 2024 | Oct 30, 2024 | $4.08 / $3.79Alpha Vantage | +7.65% beat | $2.47B No estimate | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue and income use company releases, SEC filings, Alpha Vantage or Yahoo Finance. Non-USD revenue carries its currency code. Comparisons require a paired release estimate.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $2.45B | $2.28B | $2.48B | $2.74B |
| Cost of what it sold | $876.6M | $496.3M | $661.0M | $1.18B |
| Gross profit | $1.58B | $1.78B | $1.82B | $1.56B |
| What it spent | ||||
| Research and development | $369.6M | $509.3M | $573.0M | $495.6M |
| Sales and admin | $594.8M | $683.0M | $607.3M | $709.7M |
| Other operating costs | — | $647.7M | $239.1M | $34.0M |
| Total operating expenses | $964.4M | $1.84B | $1.42B | $1.24B |
| What was left | ||||
| Operating profit | $613.8M | -$57.0M | $397.4M | $318.1M |
| Interest on debt | $67.4M | $67.5M | $67.6M | $82.3M |
| Profit before tax | $557.3M | -$211.0M | $377.7M | $132.4M |
| Tax | $90.8M | -$162.6M | $58.2M | $34.9M |
| Net profit | $466.5M | -$48.4M | $319.5M | $97.5M |
| EBITDA | $826.9M | $56.7M | $621.5M | $450.8M |
This stock is in a strong uptrend, and looks overbought after a fast run-up.
Trend
Strong uptrend
85 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
Biogen Inc. Estimates – BCS:BIIB0
NeutralOct 23Biogen Inc. Estimates – NASDAQ:BIIB
NeutralOct 23Biogen Inc Shs Cert Deposito Arg Repr 1/13 Sh Estimates – BCBA:BIIB.CI
NeutralOct 23Can Biogen (BIIB) Support A Discount With Cash Flow Growth?
Leans bullishOct 23Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2026 Business and Financial Updates
Leans bullishOct 23Sanofi bets on the white jersey to bring health awareness to the Tour de France
NeutralOct 22Burlington biotech cuts nearly half its staff to focus on weight maintenance device
NeutralOct 22Biogen Inc. stock outperforms competitors on strong trading day
BullishOct 22